Statins: Evidence of effectiveness in older patients

Geriatrics

Volumn 58, Issue 5, 2003, Pages 35-42

  Nash, David T ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

HMG CoA reductase inhibitors; Hypercholosterolemia lipids; LDL cholftterol; Statins

Indexed keywords

ANTIFUNGAL AGENT; C REACTIVE PROTEIN; CYCLOSPORIN; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PADGEM PROTEIN; PRAVASTATIN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; GERIATRIC PATIENT; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; PRIMARY PREVENTION; REVIEW; RISK MANAGEMENT; SIDE EFFECT; STROKE;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0038326952     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2001:1-35.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. (Cholesterol And Recurrent Events Investigators). N Engl J Med 1996; 335(14):1001-9.
3. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934):1383-9.
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. (WOSCOPS). N Engl J Med 1995; 333(20):1301-7.
5. Bandyopadhyay S, Bayer AJ, O'Mahony MS. Age and gender bias in statin trials. QJM 2001; 94(3):127-32.
6. Aronow WS. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol >125 mg/dl. Am J Cardiol 1998; 82(5):668-9.
7. Foody JM, Rathore S, Galusha D, et al. Older adults with myocardial infarction not receiving optimal lipid lowering management: Insights from the national AMI project [abstract]. Circulation 2001; 104:11-790.
8. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999; 20(10):725-41.
9. TIME Investigators. Trial of invasive versus medical therapy in older patients with chronic symptomatic coronaryartery disease (TIME): A randomised trial. Lancet 2001; 358(9286):951-7.
10. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet 1997; 350(9076):461-8.
11. Ford ES, Giles WH, Dietz WH. Prevalence of the matabolic syndrome among US adults. Findings from the third National Health and Nutrition Examination Survey. (NHANES III) JAMA 2002; 287(3):356-9.
12. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486-97.
13. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104(25):3046-51.
14. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103(3):357-62.
15. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287(11):1420-6.
16. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996; 18(11):669-75.
17. Romano M, Marulli C, Ciabattoni G, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients [abstract]. Circulation 1998; 98:1-801.
18. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1):64-70.
19. Madej A, Kalina Z, Okopieri B, et al. The release of tumor necrosis factor- alpha by cultured macrophages from hyperlipidemic patients treated with fluvastatin [abstract]. Eur J Clin Pharmacol 1997; 52:A76.
20. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21(11):1712-9.
21. Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999; 95(5):229-34.
22. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356(9247):1627-31.
23. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283(24):3205-10.
24. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161(11):1405-10.
25. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001; 88(6):693-5.
26. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001; 285(13):1711-8.
27. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3,260 patients with unstable angina: Results from the LIPID study. Lancet 2000; 356(9245):1871-5.
28. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285(4):430-6.
29. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103(1):38-44.
30. Jackevicius CA, Mamdani M, Tu JV. Adherence with chronic statin therapy in patients with and without acute coronary syndromes: Use without long-term benefit [abstract]. Circulation 2001; 104:11-829.
31. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolism-monograph for physicians. Arch Intern Med 2000; 160(15):2273-80.